Ohio has experienced an epidemic of prescription drug abuse and dependence, specifically involving opioid controlled substances. Because of this epidemic, more physicians are offering opioid maintenance treatment for persons suffering from addiction. Suboxone, a combination of buprenorphine and naloxone, has assisted in countless recoveries from opioid addiction, but regrettably, Ohio has likewise seen a rise in diversion and misuse of Suboxone and other buprenorphine products.
As a result, the State Medical Board of Ohio (“Board”) recently released proposed administrative rules concerning the provision of office-based treatment of opioid addiction using buprenorphine products such as Suboxone. Such rules, while not yet adopted, would be added to the Board’s rules pertaining to controlled substances, Chapter 4731-11 of the Ohio Administrative Code. More.